Know How Bexagliflozin Stacks Up to Other SGLT2 Inhibitors
New bexagliflozin (Brenzavvy) will try to shake up the SGLT2 inhibitor market.
That’s because bexagliflozin will cost about $50/mo...versus about $600/mo for other SGLT2 inhibitors (dapagliflozin, etc).
But bexagliflozin won’t be covered by most payers yet...and it will only be available through a single online pharmacy at first. Expect distribution to broaden over the next couple months.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote